Is VERU or MIST more profitable?

Veru's return on equity of -47.58% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Milestone Pharmaceuticals N/A -288.33% -58.27%

Does the media favor VERU or MIST?

In the previous week, Milestone Pharmaceuticals had 13 more articles in the media than Veru. MarketBeat recorded 21 mentions for Milestone Pharmaceuticals and 8 mentions for Veru. Veru's average media sentiment score of 0.95 beat Milestone Pharmaceuticals' score of -0.08 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VERU or UNCY more profitable?

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Unicycive Therapeutics N/A -91.50% -61.47%

Does the media favor VERU or UNCY?

In the previous week, Unicycive Therapeutics had 22 more articles in the media than Veru. MarketBeat recorded 30 mentions for Unicycive Therapeutics and 8 mentions for Veru. Veru's average media sentiment score of 0.95 beat Unicycive Therapeutics' score of 0.59 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, VTVT or VERU?

Veru has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio vTv Therapeutics $1.02M 116.35 -$26.97M -$1.06 N/A Veru $16.89M 2.76 -$22.73M -$0.89 N/A

Is VTVT or VERU more profitable?

vTv Therapeutics' return on equity of -6.27% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Veru N/A -47.58% -35.83%

Does the media refer more to VTVT or VERU?

In the previous week, Veru had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 8 mentions for Veru and 3 mentions for vTv Therapeutics. Veru's average media sentiment score of 0.95 beat vTv Therapeutics' score of -0.43 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is VERU or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Polaryx Therapeutics N/A N/A N/A

Does the media favor VERU or PLYX?

In the previous week, Veru had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 8 mentions for Veru and 7 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.04 beat Veru's score of 0.95 indicating that Polaryx Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRXP or VERU more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Veru N/A -47.58% -35.83%

Does the media favor NRXP or VERU?

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Veru. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 8 mentions for Veru. Veru's average media sentiment score of 0.95 beat NRx Pharmaceuticals' score of 0.16 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veru 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Veru (VERU) Competitors

$2.73 +0.03 (+1.11%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.68 -0.05 (-1.83%)

As of 08/14/2026 07:34 PM Eastern

Compare

VERU vs. MIST, UNCY, VTVT, PLYX, and NRXP

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Milestone Pharmaceuticals (MIST), Unicycive Therapeutics (UNCY), vTv Therapeutics (VTVT), Polaryx Therapeutics (PLYX), and NRx Pharmaceuticals (NRXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Milestone Pharmaceuticals?

Veru (NASDAQ:VERU) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Veru has a beta of -1.15, indicating that its share price is 215% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

47.2% of Veru shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Veru currently has a consensus price target of $24.50, indicating a potential upside of 797.44%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 559.09%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Veru's return on equity of -47.58% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

In the previous week, Milestone Pharmaceuticals had 13 more articles in the media than Veru. MarketBeat recorded 21 mentions for Milestone Pharmaceuticals and 8 mentions for Veru. Veru's average media sentiment score of 0.95 beat Milestone Pharmaceuticals' score of -0.08 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veru has higher revenue and earnings than Milestone Pharmaceuticals. Veru is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A
Milestone Pharmaceuticals	$1.55M	88.35	-$63.06M	-$0.69	N/A

Summary

Milestone Pharmaceuticals beats Veru on 9 of the 16 factors compared between the two stocks.

How does Veru compare to Unicycive Therapeutics?

Veru (NASDAQ:VERU) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Veru presently has a consensus price target of $24.50, indicating a potential upside of 797.44%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 231.22%. Given Veru's higher probable upside, equities research analysts plainly believe Veru is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

47.2% of Veru shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Veru has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A

Veru has a beta of -1.15, meaning that its stock price is 215% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 22 more articles in the media than Veru. MarketBeat recorded 30 mentions for Unicycive Therapeutics and 8 mentions for Veru. Veru's average media sentiment score of 0.95 beat Unicycive Therapeutics' score of 0.59 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Summary

Veru beats Unicycive Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Veru compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Veru has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	116.35	-$26.97M	-$1.06	N/A
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A

In the previous week, Veru had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 8 mentions for Veru and 3 mentions for vTv Therapeutics. Veru's average media sentiment score of 0.95 beat vTv Therapeutics' score of -0.43 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Veru has a beta of -1.15, meaning that its stock price is 215% less volatile than the broader market.

vTv Therapeutics' return on equity of -6.27% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Veru	N/A	-47.58%	-35.83%

vTv Therapeutics presently has a consensus price target of $55.83, indicating a potential upside of 85.37%. Veru has a consensus price target of $24.50, indicating a potential upside of 797.44%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Veru beats vTv Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Veru compare to Polaryx Therapeutics?

Veru (NASDAQ:VERU) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Polaryx Therapeutics' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Polaryx Therapeutics	N/A	N/A	N/A

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Polaryx Therapeutics has lower revenue, but higher earnings than Veru. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A

Veru currently has a consensus target price of $24.50, suggesting a potential upside of 797.44%. Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 194.87%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Veru had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 8 mentions for Veru and 7 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.04 beat Veru's score of 0.95 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Polaryx Therapeutics beats Veru on 8 of the 13 factors compared between the two stocks.

How does Veru compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

NRx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Veru	N/A	-47.58%	-35.83%

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NRx Pharmaceuticals presently has a consensus price target of $34.50, suggesting a potential upside of 955.05%. Veru has a consensus price target of $24.50, suggesting a potential upside of 797.44%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Veru.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veru has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	96.32	-$28.62M	-$0.55	N/A
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Veru. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 8 mentions for Veru. Veru's average media sentiment score of 0.95 beat NRx Pharmaceuticals' score of 0.16 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

NRx Pharmaceuticals has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Veru has a beta of -1.15, meaning that its share price is 215% less volatile than the broader market.

Summary

NRx Pharmaceuticals beats Veru on 8 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.55M	$11.80B	$7.03B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.64%
P/E Ratio	-3.07	779.99	271.26	25.40
Price / Sales	2.76	749.29	623.00	105.36
Price / Cash	N/A	89.04	75.70	53.27
Price / Book	1.64	11.60	12.92	6.21
Net Income	-$22.73M	$2.77B	$3.45B	$347.71M
7 Day Performance	17.17%	0.14%	1.16%	1.08%
1 Month Performance	16.17%	0.65%	2.17%	1.87%
1 Year Performance	-23.96%	145.68%	62.38%	20.79%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	2.1998 of 5 stars	$2.73 +1.1%	$24.50 +797.4%	-24.0%	$46.55M	$16.89M	N/A	230	Earnings Report Analyst Downgrade
MIST Milestone Pharmaceuticals	1.7708 of 5 stars	$1.12 +0.9%	$7.25 +547.3%	-35.3%	$138.19M	$1.55M	N/A	30	Trending News Earnings Report Analyst Revision
UNCY Unicycive Therapeutics	3.3145 of 5 stars	$5.05 +0.8%	$21.75 +330.7%	+17.2%	$137.24M	$680K	N/A	9	Trending News Earnings Report Analyst Forecast Analyst Revision
VTVT vTv Therapeutics	2.8051 of 5 stars	$32.39 +0.1%	$56.67 +75.0%	+90.0%	$127.42M	$1.02M	N/A	9	Analyst Downgrade
PLYX Polaryx Therapeutics	4.467 of 5 stars	$2.19 -5.2%	$8.50 +288.1%	N/A	$115.14M	N/A	N/A	11	News Coverage Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. MIST, UNCY, VTVT, PLYX, and NRXP

How does Veru compare to Milestone Pharmaceuticals?

Summary

How does Veru compare to Unicycive Therapeutics?

Summary

How does Veru compare to vTv Therapeutics?

Summary

How does Veru compare to Polaryx Therapeutics?

Summary

How does Veru compare to NRx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. MIST, UNCY, VTVT, PLYX, and NRXP

How does Veru compare to Milestone Pharmaceuticals?

Which has more volatility & risk, VERU or MIST?

Do institutionals & insiders believe in VERU or MIST?

Do analysts prefer VERU or MIST?

Is VERU or MIST more profitable?

Does the media favor VERU or MIST?

Which has better earnings and valuation, VERU or MIST?

Summary

How does Veru compare to Unicycive Therapeutics?

Do analysts rate VERU or UNCY?

Do insiders and institutionals believe in VERU or UNCY?

Which has preferable earnings and valuation, VERU or UNCY?

Which has more risk and volatility, VERU or UNCY?

Does the media favor VERU or UNCY?

Is VERU or UNCY more profitable?

Summary

How does Veru compare to vTv Therapeutics?

Do institutionals and insiders believe in VTVT or VERU?

Which has higher earnings and valuation, VTVT or VERU?

Does the media refer more to VTVT or VERU?

Which has more volatility and risk, VTVT or VERU?

Is VTVT or VERU more profitable?

Do analysts prefer VTVT or VERU?

Summary

How does Veru compare to Polaryx Therapeutics?

Is VERU or PLYX more profitable?

Do insiders & institutionals hold more shares of VERU or PLYX?

Which has stronger earnings and valuation, VERU or PLYX?

Do analysts prefer VERU or PLYX?

Does the media favor VERU or PLYX?

Summary

How does Veru compare to NRx Pharmaceuticals?

Is NRXP or VERU more profitable?

Do insiders and institutionals have more ownership in NRXP or VERU?

Do analysts recommend NRXP or VERU?

Which has better valuation and earnings, NRXP or VERU?

Does the media favor NRXP or VERU?

Which has more volatility & risk, NRXP or VERU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools